Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2012 | short review | Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2012
Autor:
MD Robert Zeiser

Abstract

The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe